1-3 of 3
Karen Flatten
Close
Sort by
Journal Articles

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide

Clinical Trials & Observations
Judith E. Karp, Karen Flatten, Eric J. Feldman, Jacqueline M. Greer, David A. Loegering, Rebecca M. Ricklis, Lawrence E. Morris, Ellen Ritchie, B. Douglas Smith, Valerie Ironside, Timothy Talbott, Gail Roboz, Son B. Le, Xue Wei Meng, Paula A. Schneider, Nga T. Dai, Alex A. Adjei, Steven D. Gore, Mark J. Levis, John J. Wright, Elizabeth Garrett-Mayer, Scott H. Kaufmann
Journal: Blood
Blood (2009) 113 (20): 4841–4852.
https://doi.org/10.1182/blood-2008-08-172726
Published: 2009
Includes: Supplemental data
Journal Articles

Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance

Joya Chandra, Jeannette Tracy, David Loegering, Karen Flatten, Srdan Verstovsek, Miloslav Beran, Mercedes Gorre, Zeev Estrov, Nicholas Donato, Moshe Talpaz, Charles Sawyers, Kapil Bhalla, Judith Karp, Edward Sausville, Scott H. Kaufmann
Journal: Blood
Blood (2006) 107 (6): 2501–2506.
https://doi.org/10.1182/blood-2005-07-2966
Published: 2006
Journal Articles

Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine

Ruben A. Mesa, David Loegering, Heather L. Powell, Karen Flatten, Sonnet J. H. Arlander, Nga T. Dai, Michael P. Heldebrant, Benjamin T. Vroman, B. Douglas Smith, Judith E. Karp, Cynthia J. Ten Eyck, Charles Erlichman, Scott H. Kaufmann, Larry M. Karnitz
Journal: Blood
Blood (2005) 106 (1): 318–327.
https://doi.org/10.1182/blood-2004-09-3523
Published: 2005